VolitionRx Limited to Hold Earnings Conference Call on November 13, 2026

VolitionRx Limited to Host Third Quarter 2026 Conference Call

VolitionRx Limited, trading under the symbol VNRX on NYSE AMERICAN, has scheduled an important event for its investors and stakeholders on November 13, 2026. The conference call is set to begin at 8:30 a.m. U.S. Eastern Time and aims to discuss the company’s financial results for the third quarter of 2026 along with significant updates regarding its business operations.

Event Details

The event will be hosted by Rodney Rootsaert, Corporate Secretary, alongside Cameron Reynolds, President and Chief Executive Officer, and Terig Hughes, Chief Financial Officer. During the call, the executives will outline key developments from the third quarter, including subsequent events and anticipated milestones.

Participants can dial in according to their location:

- U.S. & Canada: 1-877-407-9716 (toll free)
- U.K.: 0 800 756 3429 (toll free)
- International: 1-201-493-6779

A specific Conference ID to join the call is set at 13763536.

Live Webcast & Replay

In addition to the live call, there will be an audio webcast that interested parties can access through the provided link. For those who cannot attend the live session, a telephone replay will be available until November 27, 2026. Participants looking for the replay can use the following numbers:

- U.S. & Canada: 1-844-512-2921 (toll-free)
- International: 1-412-317-6671

The replay pin number for access is also 13763536.

About VolitionRx

VolitionRx is a multinational enterprise committed to advancing the field of epigenetics with the express goal of saving lives and enhancing health outcomes. The company works towards achieving earlier detection of life-altering diseases, including certain cancers and conditions associated with NETosis, such as sepsis.

Through its various subsidiaries, VolitionRx is focusing on the development and commercialization of affordable, user-friendly blood tests. These advancements aim to facilitate the early detection and monitoring of a wide array of diseases which, in turn, is believed to not only extend patient lifespans but also improve their quality of life significantly.

This upcoming conference call represents a crucial opportunity for stakeholders to gain insights into the company’s current standing, forthcoming plans, and overall trajectory in the healthcare landscape. Investors and interested parties are encouraged to participate actively and stay informed of VolitionRx's developments.

For more information and to follow the latest updates from the company, stakeholders can visit Volition’s official website or contact their media relations team directly.